Distinguishing between benign and malignant thyroid nodules (TNs) is challenging due to their overlapping imaging features. The rapid advancement of artificial intelligence (AI) in medical image ...
Thyroid cancer is significantly more common in women than in them. Here, doctors reveal the number-one sign of thyroid cancer ...
The thyroid-gut axis represents a dynamic interaction between the intestinal microbiota and thyroid function, with growing evidence linking gut dysbiosis to thyroid diseases. The gut microbiome, ...
Abstract: Thyroid nodule segmentation from ultrasound images is an important step for early diagnosis of thyroid diseases. This paper introduces a novel encoder-decoder network architecture, called ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulsetm technology using proprietary Nanosecond Pulsed Field Ablationtm (nanosecond PFA or nsPFAtm) energy, today announced clinical ...
Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. HAYWARD, Calif., March 09, 2026--(BUSINESS ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of ...
The CellFX nsPFA percutaneous electrode system. [Image courtesy of Pulse Biosciences] Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results